MDL | - |
---|---|
Molecular Weight | 445.42 |
Molecular Formula | C25H30Cl2N2O |
SMILES | OC(C1CCCCN1)C2=CC(C3(C[C@H](C4)C5)C[C@H]5C[C@H]4C3)=NC(C(Cl)=C6)=C2C=C6Cl |
NSC305787 is an inhibitor of ezrin with a K d of 5.85 μM, inhibits the phosphorylation of ezrin caused by PKCΙ with an IC 50 of 8.3 μM, has antitumor activity.
NSC305787 is an inhibitor of ezrin with a K d of 5.85 μM, and has antitumor activity. NSC305787 inhibits PKCΙ phosphorylation of Ezrin, Moesin, Radixin, MBP, with IC 50 s of 8.3, 9.4, 55, 58.9 μM, respectively. NSC305787 binds to PKCΙ with a K d value of 172.4 μM, and inhibits ezrin T567 phosphorylation primarily via its binding to ezrin and not through inhibition of PKCΙ kinase activity. NSC305787 (1, 10 μM) shows inhibitory activity against ezrin-mediated invasion of K7M2 osteosarcoma (OS) cells. Moreover, NSC305787 (10 μM) reduces cell motility phenotypes in zebrafish and blocks OS metastatic growth in lung organ culture [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NSC305787 (0.240 mg/kg/day, i.p.) suppresses ezrin-dependent osteosarcoma metastatic growth in mouse lung [1] . NSC305787 (240 μg/kg, i.p.) dramatically inhibits pulmonary metastasis in a transgenic mouse model of osteosarcoma (Osx-Cre + p53 fl/fl pRB fl/fl ) and shows a more favorable pharmacokinetic profile compared with NSC668394 in the mouse model [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 6 mg/mL ( 13.47 mM ; Need ultrasonic and warming)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2451 mL | 11.2254 mL | 22.4507 mL |
5 mM | 0.4490 mL | 2.2451 mL | 4.4901 mL |
10 mM | 0.2245 mL | 1.1225 mL | 2.2451 mL |